Fig. 7: SLC7A6 mediated CD8 + T cell function in cisplatin resistant bladder cancer microenvironment through alteration of methionine absorption.

A Effects of BCH or MeAIB on supernatant of T24CR cells affected function of CD8 + T cell. Data are presented as the mean ± SD. ***p < 0.001, **p < 0.01 versus Sup. B RT-qPCR showed transcripts of SLC transporter in T24 and T24-CR cells. C The protein expression of SLC7A6 and SLC43A2 from patient derived CD8 + T cells and BCa cells. D Relative expression of MAT2A, circARHGAP10, SLC7A6 and CD8A in TMA. The contingency correlating the staining intensity of relative marker was analyzed with chi-squared test. E SLC7A6 knockdown efficiency in T24-CR cells. F Effects of expression of H3K79me2/STAT5 in CD8 + T cell with culturing with supernatants from shSLC7A6-T24CR cells. G Effects of shSLC7A6-T24CR cells affected function of CD8 + T cell. Data are presented as the mean ± SD. ***p < 0.001 versus Complete Medium. H SLC7A6 expression in BCa tissue samples from recurrence after 6 months (n = 9) or recurrence in 6 months (n = 8). I Relative SLC7A6 expression from paired BCa tissue samples from patients received cisplatin based chemotherapy (n = 5). J Combination of BCH with anti-PD-L1 treatment on MB49-CR cell xenograft model (6 mice were enrolled in each treatment group). K Tumor volumes were presented as mean ± SD. ***p < 0.001 versus LV-NC group. L Tumor weight were presented as mean ± SD. ***p < 0.001, *p < 0.05 versus LV-NC group.